Age (≥50 vs. <50 years)
|
1.329
|
0.186
| | |
1.384
|
0.055
|
Not significant
| |
Gender (female vs. male)
|
1.087
|
0.795
| | |
0.914
|
0.737
| | |
HBeAg (positive vs. negative)
|
1.407
|
0.132
| | |
1.216
|
0.290
| | |
Tumor size (≥5 vs. <5 cm)
|
1.618
|
0.024
|
Not significant
| |
1.618
|
0.004
|
1.650 (1.162–2.342)
|
0.005
|
Tumor number (multiple vs. single)
|
2.175
|
0.010
|
Not significant
| |
1.796
|
0.028
|
2.104 (1.218–3.635)
|
0.008
|
Pathologic grades (IV/III/II/I)
|
1.365
|
0.070
|
1.613 (1.129–2.305)
|
0.009
|
1.100
|
0.476
| | |
Microvascular thrombus (yes vs. no)
|
2.038
|
0.010
|
2.688 (1.534–4.710)
|
0.001
|
1.128
|
0.640
| | |
Tumor capsule (without/incomplete/complete)
|
1.201
|
0.148
| | |
1.030
|
0.771
| | |
AFP (>25 vs. ≤25 ng/mL)
|
1.291
|
0.240
| | |
1.030
|
0.863
| | |
ALT (>40 vs. ≤40 IU/L)
|
1.064
|
0.774
| | |
1.088
|
0.621
| | |
AST (>45 vs. ≤45 IU/L)
|
1.657
|
0.018
|
Not significant
| |
1.688
|
0.002
|
1.486 (1.057–2.090)
|
0.023
|
ALB (≥35 vs. <35 g/L)
|
0.294
|
0.008
|
Not significant
| |
0.633
|
0.316
| | |
TBIL (>20.5 vs. ≤20.5 μmol/L)
|
1.566
|
0.077
|
Not significant
| |
1.098
|
0.672
| | |
Prothrombin time (>13.5 vs. ≤13.5 s)
|
0.867
|
0.557
| | |
0.814
|
0.283
| | |
Antiviral treatment (yes vs. no)
|
0.499
|
0.001
|
0.475 (0.309–0.729)
|
0.001
|
0.710
|
0.042
|
Not significant
|
0.120
|
Recurrence (yes vs. no)
|
9.514
|
<0.001
|
9.954 (4.781–20.725)
|
<0.001
| | | | |